Search results for: Innovation Policy Prize
Filter search results
Accountable Health Care: Is it compatible with social solidarity?
1 February 1998
…Although that point should be obvious to any thoughtful person, it is overlooked with distressing regularity in the debate on health policy. After considering the contribution of ‘managed care’ to…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…support for CARB-X. Beyond EU support for CARB-X the policy need is for “pull” incentives that create financial rewards for the successful development of a new product. These are currently…
The Long-term Sustainability of the NHS and Adult Social Care
13 April 2017
…has previously been suggested that 30-40% of Select Committee recommendations end up as government policy, but will this happen here? As detailed below, one of the recommendation is ‘realistic and…
Professor Lotte Steuten Appointed OHE Vice President and Head of Consulting
8 January 2019
…the Hutchinson Institute for Cancer Outcomes Research (HICOR) at the Fred Hutchinson Cancer Research Center, and an affiliate associate professor in the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute…
Is collaboration between and across regulatory and HTA agencies the answer to access challenges?
12 November 2024
…agencies In the HTA space, collaboration has only started to gain momentum in recent years. While collaboration can encompass various aspects ( HTAi Policy Forum, 2024), from professional platforms such…
Amanda Cole
30 May 2014
…at UCL and a member of ISPOR’s Health Science Policy Council. Her research focuses on value-based payment models, incentives for innovation, pharmaceutical market design, and the intersection of HTA policy…
Interdependencies in Funding Medical Research in the UK
2 July 2014
Cancer Research UK has recently released a report completed for it by OHE and the Science Policy Research Unit (SPRU) at the University of Sussex that focuses on the strength…
New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
7 March 2017
Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the 2016 ICER Membership Policy…
New Business Models for Antibiotics
22 April 2014, 11:00pm
Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance….